Global pharmaceutical leader Lupin Limited announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility…
The World Health Organization has released “The Role of Parliaments and Parliamentarians in Strengthening Health Security Preparedness,” an online training course designed to equip parliamentarians with the knowledge and tools…
In April, at the United Nations Headquarters in New York, governments reaffirmed their commitment to the Programme of Action from the 1994 International Conference on Population and Development (ICPD). The…
Today, AbbVie announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (RINVOQ®; 15…
Daiichi Sankyo (TSE: 4568) has inaugurated a new affiliate dedicated to its oncology business in Athens, Greece, underscoring its commitment to addressing the needs of cancer patients in Europe. Thomais…
Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and…
This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates…
Sinaptica, a clinical-stage company pioneering personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the publication of a study in Alzheimer’s Research & Therapy. The study utilized MRI…
Harrow, a prominent North American eyecare pharmaceutical firm, announced today its agreement with Apexus to include IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other key products in the 340B Prime…
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company focused on developing and commercializing innovative products, announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire…
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. APEIRON holds royalty rights to QARZIBA® (dinutuximab beta), a treatment…
Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has…